New first-in-human study explores immune-engineered cell therapy approach for type 1 diabetes. New research presented at the International Society for Stem Cell Research (ISSCR) 2026 Annual Meeting explores an approach that could expand the potential of cell replacement therapy for type 1 diabetes by evaluating whether immune-engineered, allogeneic insulin-producing cells can survive and function without chronic immunosuppression.
A apuração publicada por medicalxpress.com vira base para uma leitura editorial direta e contextualizada.
Trechos de apoio da pauta: New research presented at the International Society for Stem Cell Research (ISSCR) 2026 Annual Meeting explores an approach that could expand the potential of cell replacement therapy for type 1 diabetes by evaluating whether immune-engineered, allogeneic insulin-producing cells can survive and function without chronic immunosuppression.
- Ponto de atenção: first.
- Ponto de atenção: human.
- Ponto de atenção: study.
Em resumo, a leitura editorial acompanha o impacto do tema no nicho Fitness.
:quality(85)/a3030f3c-45cb-45f2-84a8-8b29673fabad.jpeg)